InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James...
November 24 2020 - 8:17AM
via InvestorWire – InvestorBrandNetwork (“IBN”), a
multifaceted communications organization engaged in connecting
public companies to the investment community, is pleased to
announce the release of the latest episode of the Stock2Me
Podcast as part of its sustained effort to provide specialized
content distribution via widespread syndication channels.
Stock2Me Podcasts feature a fascinating array of
companies and individuals, many of whom are actively
revolutionizing age-old business practices within their respective
markets.
Stock2Me’s latest podcast features James
Sapirstein, president & CEO of AzurRx BioPharma Inc. (NASDAQ:
AZRX).
“AzurRx Bio has been around for five years. …
Our main product, MS1819, is being studied in chronic pancreatitis
and in the GI effects of cystic fibrosis,” Sapirstein stated in the
interview. “The market for this particular product (in chronic
pancreatitis, competing against pancreatic enzyme replacement
therapy (PERT) is about $1 billion outside of the United States and
several hundred million dollars inside the United States. The other
market is cystic fibrosis. It’s over a $2 billion market worldwide
for PERT.”
AzurRx currently has two ongoing clinical trials
for MS1819. The first is a Phase 2 Cystic Fibrosis Combination
Trial examining MS1819 in combination with PERT, which is expected
to produce topline data in Q2 2021.
The company’s second ongoing trial is a Phase 2b
Cystic Fibrosis Option 2 monotherapy trial that is expected to
produce topline data in Q1 2021. Describing this study, Sapirstein
noted, “This is a crossover design study. We place patients on
PERT, the existing standard of care therapy, and we also put
another line of patients on our drug. These patients take the drugs
for three weeks, then we crossover. These patients are not being
studied versus placebo. … We’re actually adding another arm where
we can dose escalate, because we enrolled the trial very quickly
despite COVID. … Because of that, we decided to get some more data
out of this trial with another arm.”
Sapirstein went on to discuss the impacts of
COVID-19 on AzurRx. The company made a number of adjustments to its
clinical development strategy in an effort to better navigate the
pandemic. “I immediately, back in February, told my clinical group
that this virus is going to be pretty bad and a lot of countries
are going to start shutting down. For our combination trial, we
decided to start getting some backups. We called the folks in
Europe that were working on our trial and told them to get as many
patients as possible,” he said. “We also opened up Poland and
Turkey. … It takes several months to get these sites up and running
and calibrated, so, on the combination trial, we lost about a month
on COVID, but not a significant amount of time.”
“In the United States, we took a very different
approach with our Option 2 trial,” Sapirstein continued. “Because
these patients don’t need a lot of bloodwork, we decided to
sequester these folks in hotels. Obviously, there was a lot of
hotel space available. We put that into our protocol; we got it
approved by the FDA. … That’s how we were able to do it this
quickly.”
Join InvestorBrandNetwork’s Stuart Smith and
AzurRx’s James Sapirstein in exploring how AzurRx is working to
redefine the standard of care for patients living with cystic
fibrosis and chronic pancreatitis.
To catch the entire episode and subscribe for
future episodes please visit: https://podcast.stock2me.com
The latest installment of The Stock2Me Podcast
continues to reinforce InvestorBrandNetwork’s commitment to
the expansion of its robust network of brands, client partners,
followers and the growing IBN Podcast Series. For more than 15
years, IBN has leveraged this commitment to provide unparalleled
distribution and corporate messaging solutions to 500+ public
and private companies.
To learn more about IBN’s achievements and milestones via a
visual timeline visit: https://IBN.fm/TimeLine
About InvestorBrandNetwork
The InvestorBrandNetwork (“IBN”)
consists of financial brands introduced to the investment public
over the course of 15+ years. With IBN, we have amassed a
collective audience of millions of social media followers. These
distinctive investor brands aim to fulfill the unique needs of a
growing base of client-partners. IBN will continue to expand our
branded network of highly influential properties, leveraging the
knowledge and energy of specialized teams of experts to serve our
increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and
its affiliate brands, IBN provides: (1) access to a network of wire
solutions via InvestorWire to reach all target markets,
industries and demographics in the most effective manner possible;
(2) article and editorial syndication to 5,000+ news outlets; (3)
enhanced press release solutions to ensure maximum impact; (4)
full-scale distribution to a growing social media audience; (5) a
full array of corporate communications solutions; and (6) a total
news coverage solution.
For more information on IBN,
visit https://www.InvestorBrandNetwork.com.
Please see full terms of use and disclaimers on
the InvestorBrandNetwork website, applicable to all content
provided by IBN, wherever published or
re-published: https://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All forward-looking statements are inherently uncertain as
they are based on current expectations and assumptions concerning
future events or future performance of the company. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which are only predictions and speak only as of the
date hereof. In evaluating such statements, prospective investors
should review carefully various risks and uncertainties identified
in this release and matters set in the company's SEC filings. These
risks and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
InvestorBrandNetwork (IBN)Los Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Apr 2023 to Apr 2024